-+ 0.00%
-+ 0.00%
-+ 0.00%

Universal Health Realty (UHT) FFO Loss Challenges Income Focused Bullish Narratives

Simply Wall St·02/27/2026 00:45:27
Listen to the news

Universal Health Realty Income Trust (UHT) has just wrapped up FY 2025 with Q4 revenue of US$23.3 million and basic EPS of US$0.31, alongside Funds From Operations of a loss of US$35.9 million that will likely catch investors’ attention. The trust has seen quarterly revenue move from US$24.8 million in Q3 2024 to between US$24.0 million and US$25.7 million through 2025, while basic EPS ranged from US$0.29 to US$0.35 across those same quarters. This sets up a picture where headline profitability metrics, including a 17.8% net margin over the last 12 months, sit against a well flagged earnings decline and a relatively high dividend yield. Overall, the latest numbers point to margins that have compressed versus the prior year, which puts extra focus on how sustainable the current income profile really is for shareholders.

See our full analysis for Universal Health Realty Income Trust.

With the raw results on the table, the next step is to see how these figures line up with the stories investors usually tell about UHT, and where the earnings and margin trends either support or challenge those narratives.

Curious how numbers become stories that shape markets? Explore Community Narratives

NYSE:UHT Earnings & Revenue History as at Feb 2026
NYSE:UHT Earnings & Revenue History as at Feb 2026

FFO Swing and Margin Pressure Stand Out

  • Funds From Operations moved from US$12.2 million in Q3 2025 to a loss of US$35.9 million in Q4 2025, while net profit margin over the last 12 months was 17.8% compared with 19.2% a year earlier.
  • Critics highlight that a five year annualized earnings decline of 25.2% and weaker interest coverage line up with this FFO loss. At the same time, the trailing 12 month net income of US$17.6 million still shows the business generating profit, which creates a tension between the bearish focus on declining earnings and the fact that margins, while lower, remain positive.
    • Bears point to the 17.8% margin and the interest coverage shortfall as signs that profitability and financing costs are pressing against each other.
    • At the same time, quarterly net income figures between US$4.0 million and US$4.8 million through FY 2025 indicate the core operations continued to produce profit even in a year where longer term earnings trends were weak.

Revenue Growth Trails Market Benchmarks

  • Over the last year, UHT’s revenue growth is about 3% compared with a 10.4% reference rate for the wider US market, and FY 2025 quarterly revenue ranged between US$23.3 million and US$25.7 million.
  • What stands out for the bearish narrative is that slower revenue growth sits alongside the multi year 25.2% annualized earnings decline. Even so, the trailing 12 month revenue of US$99.2 million and net income of US$17.6 million still support a high dividend yield of 6.74%, so the income story continues even as growth lags.
    • Skeptics argue that modest 3% revenue growth gives less room to absorb rising expenses or interest costs highlighted in the weak coverage metrics.
    • Income focused investors may instead look at the 6.74% dividend yield and the consistent US$99 million to US$101 million revenue range over recent 12 month periods as evidence of ongoing cash generation capacity.

P/E Premium Versus Peers and Dividend Trade Off

  • UHT trades on a trailing P/E of 34.8x, above the Global Health Care REITs average of 25.9x and peer average of 21.3x, while offering a 6.74% dividend yield and a 17.8% net margin.
  • Supporters of a more constructive view argue that the combination of a high dividend yield and a P/E that is below the Health Care REITs industry average of 38.9x might justify some premium. However, the five year 25.2% annualized earnings decline and weaker interest coverage challenge a bullish case that focuses mainly on income and relative P/E levels.
    • On one hand, the 6.74% yield and positive trailing earnings can be read as appealing income characteristics at a share price of US$44.19.
    • On the other, paying 34.8x earnings while margins have eased from 19.2% to 17.8% asks investors to accept valuation above several benchmarks even as profitability metrics have softened.

Want a clearer sense of how other investors interpret this mix of premium P/E, high yield, and softer margins for UHT? 📊 Read the what the Community is saying about Universal Health Realty Income Trust.

Next Steps

Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on Universal Health Realty Income Trust's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.

Reading all this, you can see why opinions on UHT are split. It makes sense to look through the numbers yourself and decide how you feel about the balance between income, valuation, and balance sheet risks, then check out 2 key rewards and 2 important warning signs to see the full list of issues and potential positives investors are focusing on today.

Explore Alternatives

UHT is facing weaker earnings trends, margin pressure, slower 3% revenue growth versus the wider market, and interest coverage concerns despite a relatively high dividend yield.

If those mix of pressures makes you want more cushion in your portfolio, check out our 80 resilient stocks with low risk scores to quickly spot companies with more resilient profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.